US Stock MarketDetailed Quotes

BMRN Biomarin Pharmaceutical

Watchlist
  • 70.110
  • +0.640+0.92%
Close Oct 18 16:00 ET
  • 70.060
  • -0.050-0.07%
Post 20:01 ET
13.35BMarket Cap53.11P/E (TTM)

Biomarin Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Biomarin Pharmaceutical Q3 2024 Estimates Date

Currency：USDOct 29, 2024

Estimate YoY
Revenue
702.57M
+20.86%
EPS
0.52
+148.05%
Analyst Rating
Buy

Oct 10, 2024

Biomarin Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 23 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 735.156M--
Oct 29, 20242024/Q3-- / 702.573M--
Aug 5, 20242024/Q2712.029M / 664.008M--
Apr 24, 20242024/Q1648.833M / 651.814M--
Feb 22, 20242023/Q4646.207M / 636.926M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 735.156M--
Oct 29, 20242024/Q3-- / 702.573M--
Aug 5, 20242024/Q2712.029M / 664.008M--
Apr 24, 20242024/Q1648.833M / 651.814M--
Feb 22, 20242023/Q4646.207M / 636.926M--

Unlock Free Earnings Estimates

Biomarin Pharmaceutical Earnings Reports

  • Biomarin Pharmaceutical | 10-Q: Q2 2024 Earnings Report

    Aug 5 16:38 ET

  • Biomarin Pharmaceutical | 10-Q: Q1 2024 Earnings Report

    Apr 26 14:04 ET

  • Biomarin Pharmaceutical | 10-K: FY2023 Annual Report

    Feb 26 13:36 ET

  • Biomarin Pharmaceutical | 10-Q: Q3 2023 Earnings Report

    Nov 2, 2023 14:53 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Oct 10, 2024

    Buy

    • Buy

      74.07%

    • Hold

      25.93%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data